<DOC>
	<DOC>NCT02065570</DOC>
	<brief_summary>This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.</brief_summary>
	<brief_title>Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis of Crohn's disease (CD) for at least 90 days, confirmed by endoscopy during the Screening Period. Active CD with a Crohn's Disease Activity Index (CDAI) despite treatment with oral corticosteroids and/or immunosuppressants. Mucosal ulceration on endoscopy. Subject with ulcerative colitis or indeterminate colitis. Subject who has had surgical bowel resections in the past 6 months or is planning resection. Subjects with an ostomy or ileoanal pouch. Subject with symptomatic bowel stricture or abdominal or perianal abcess. Subject who has short bowel syndrome. Chronic recurring infections or active Tuberculosis (TB).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn's Disease</keyword>
</DOC>